scholarly journals Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes

2013 ◽  
pp. 99 ◽  
Author(s):  
Elena Matteucci ◽  
Giampietro ◽  
Giampietro ◽  
Masoni ◽  
Della Bartola
Keyword(s):  
Type 2 Diabetes ◽  
Therapeutic Efficacy ◽  
Insulin Deficiency

scholarly journals Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes

2019 ◽  
Vol 7 (1) ◽  
pp. e000591 ◽  
Author(s):  
Anupam Kotwal ◽  
Candace Haddox ◽  
Matthew Block ◽  
Yogish C Kudva
Keyword(s):  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
Immune Checkpoint ◽  
Insulin Dependent Diabetes ◽  
Insulin Deficiency ◽  
Immune Mediated ◽  
Insulin Dependent ◽  
New Onset

ObjectiveInsulin-dependent diabetes can occur with immune checkpoint inhibitor (ICI) therapy. We aimed to characterize the frequency, natural history and potential predictors of ICI-induced diabetes.Research design and methodsWe reviewed 1444 patients treated with ICIs over 6 years at our cancer center, and from the 1163 patients who received programmed cell death protein 1 (PD-1) inhibitors, we identified 21 such cases, 12 of which developed new-onset insulin-dependent diabetes and 9 experienced worsening of pre-existing type 2 diabetes.ResultsICI-induced diabetes occurred most frequently with pembrolizumab (2.2%) compared with nivolumab (1%) and ipilimumab (0%). The median age was 61 years, and body mass index was 31 kg/m2, which are both higher than expected for spontaneous type 1 diabetes. Other immune-related adverse events occurred in 62%, the most common being immune mediated thyroid disease. New-onset insulin-dependent diabetes developed after a median of four cycles or 5 months; 67% presented with diabetic ketoacidosis and 83% with low or undetectable C-peptide. Autoantibodies were elevated in 5/7 (71%) at the time of new-onset diabetes. Diabetes did not resolve during a median follow-up of 1 year.ConclusionsPD-1 inhibitors can lead to insulin deficiency presenting as new-onset diabetes or worsening of pre-existing type 2 diabetes, with a frequency of 1.8 %. The underlying mechanism appears similar to spontaneous type 1 diabetes but there is a faster progression to severe insulin deficiency. Better characterization of ICI-induced diabetes will improve patient care and enhance our understanding of immune-mediated diabetes.

scholarly journals Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes

Diabetologia ◽  
2019 ◽  
Vol 62 (7) ◽  
pp. 1167-1172 ◽  
Author(s):  
Nicholas J. Thomas ◽  
Anita L. Lynam ◽  
Anita V. Hill ◽  
Michael N. Weedon ◽  
Beverley M. Shields ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
Insulin Deficiency

Therapeutic Efficacy of Catharanthus roseus in Type 1 and Type 2 Diabetes Mellitus in Wistar Rats

2017 ◽  
pp. 201-246
Author(s):  
Karuna Rasineni ◽  
Sudhakara Gujjala ◽  
Saisree Sagree ◽  
Mallaiah Putakala ◽  
Sasi Bhusana Rao Bongu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Catharanthus Roseus ◽  
Therapeutic Efficacy ◽  
Wistar Rats

Type 2 Diabetes Overtakes Type 1 in Hispanic Girls

2008 ◽  
Vol 38 (15) ◽  
pp. 18
Author(s):  
SHERRY BOSCHERT
Keyword(s):  
Type 2 Diabetes

Causes of diabetic ketoacidosis: type 1 diabetes versus type 2 diabetes

2017 ◽  
Author(s):  
Marwa Omri ◽  
Rayene Ben Mohamed ◽  
Imen Rezgani ◽  
Sana Mhidhi ◽  
Aroua Temessek ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
Diabetic Ketoacidosis
Sign in / Sign up

Export Citation Format

Share Document